ERBB2 and breast cancer: Among the 81 patients with ERBB2 amplification (ESCAT Tier IA), 15 (18.8%) were clinically HER2 negative, indicating that targeted sequencing may identify more HER2 positive breast cancers than traditional IHC/in situ hybridization assays.